The Safety and Effectiveness of Zidovudine Plus Adefovir in HIV-Infected Patients

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following symptoms or conditions are excluded:
• •Inadequate venous access.
• •Active, serious infections (other than HIV infection) requiring parenteral antibiotic therapy.
• •Clinically significant cardiac disease, including symptoms of ischemia, congestive heart failure, or clinically significant arrhythmia.
• •Active malignancy other than Kaposi's sarcoma.
• •Mental incapacity or illness that may affect compliance.
• •Concurrent Medication:
• •Excluded:
• •ddI or ddC.
• •Interferon alpha.
• •Ganciclovir.
• •Foscarnet.
• •Diuretics.
• •Investigational agents including d4T.
• •Chemotherapeutic agents.
• •Amphotericin B.
• •Aminoglycoside antibiotics.
• •Other nephrotoxic agents.
• •Immunomodulatory agents.
• •Parenteral therapy for an active, serious infection (other than HIV infection).
• •Prior Medication:
• •Excluded within 2 weeks prior to study entry:
• •ddI or ddC.
• •Interferon alpha.
• •Ganciclovir.
• •Foscarnet.
• •Diuretics.
• •Investigational agents including d4T.
• •Chemotherapeutic agents.
• •Amphotericin B.
• •Aminoglycoside antibiotics.
• •Other nephrotoxic agents.
• •Immunomodulatory agents.
• •Excluded within 4 weeks prior to study entry:
• •Systemic therapy for Kaposi's sarcoma.
• •Required:
• •AZT at a stable dose for at least 4 weeks prior to study entry. Current use of illicit drugs (e.g., heroin or cocaine). Ingestion of substantial alcohol.